DESCRIPTION
A 39-year-old Hispanic man who was recently diagnosed with stage IV NK/T-cell lymphoma nasal type from paratracheal lymph node and bone marrow biopsy (figures 1 and 2) presented to the emergency department with fever, chills and general weakness for 2 weeks. The patient was tachycardic, tachypneic and hypotensive. Physical examination showed marked hepatosplenomegaly and complete blood count revealed pancytopaenia. Liver function test demonstrated total bilirubin 19.1 mg/dL, asparate aminotransferace 144 IU/L, alamine transaminase 92 IU/L, alkaline phosphatase 595 IU/L and fibrinogen 54 mg/dL (figure 3). Iron panel revealed iron 203 μg/dL, serum ferritin 48 900 ng/mL and transferrin saturation 94%.
Subsequent positron emission tomography (PET)
and MRI demonstrated marked hepatosplenomegaly and multiple mediastinal and retroperitoneal lymph node enlargement with avid fluorodeoxyglucose update (figure 4), meeting the diagnostic criteria of haemophagocytic lymphohistiocytosis (HLH; table 1). 1 Infectious work up was all negative except Epstein-Barr virus (EBV) quantitative PCR measure at 1.7×10 9 IU/mL, for which high-dose valacyclovir was initiated. Induction chemotherapy with an ESHAP, EPOCH regimen 2 and combination chemotherapy with L-asparaginase, methotrexate, dexamethasone followed by matched unrelated donor allogeneic stem cell transplant were performed for the treatment of HLH and NK/T-cell HLH is a syndrome with clinical manifestation of fever, splenomegaly, transaminitis and cytopaenia (table 1) . It is frequently associated with underlying malignancy, rheumatoid disease, infection, genetic defect of cytotoxicity or reduced NK cell function leading to macrophages activation. 4 Etoposide including combination regimen as well as intrathecal methotrexate in patients with central nervous system (CNS) involvement are current treatment recommendations. 5 In the familial, relapsed or progressive HLH, stem cell transplant is an alternative option with 50-60% of long-term disease-free survival. 5 NK/T-cell non-Hodgkin's lymphoma (NHL) is one of the most common malignancies associated with secondary HLHs. L-asparaginase including concurrent chemoradiation treatment is the treatment of choice for NK/T-cell NHL and stem cell transplant can be considered in refractory disease or young patients who achieve complete remission. 
Learning points
▸ Macrophage activation plays a pivotal role in haemophagocytic lymphohistiocytosis (HLH) syndrome and thorough investigation for the underlying pathology including malignancy, rheumatoid disease, infection and genetic disorder are important. ▸ Pathological confirmation of haemophagocytosis in tissues is only one of the eight current clinical criteria for the diagnosis of HLH. Its demonstration is not mandatory if sufficient numbers of other criteria are met. ▸ NK/T-cell non-Hodgkin's lymphoma is the most common underlying malignancy associated with secondary HLH. L-asparaginase including combination chemotherapy is the current recommendation and allogeneic stem cell transplant can be considered in patients with refractory disease or young patients who achieve complete remission.
